Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Sur la base des 11 analystes attribuant des notes à l'action GNCAQ, mis à jour le Oct 01, 2022
Buy
Strong buy
3
Buy
5
Hold
3
Sell
0
Strong sell
0
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for GNCAQ. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: GNCAQ is a Buy candidate.
GNCAQ stock price ended at $0 on Mardi, after rising NaN%
On the latest trading day Jan 27, 2026, the stock price of GNCAQ rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 1.8K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.2K shares were traded, amounting to a market value of approximately --.
Signaux Techniques de GNCAQ
Résumé des Signaux Techniques
Acheter des signaux 0
Signaux neutres 6
Signaux de vente 1
Strong Sell
Sell
Neutral
Buy
Strong Buy
GNCAQ présente actuellement 0 signaux d'achat et 1 signaux de vente. L'action est en tendance haussière depuis 12:00 AM, avec une variation totale du prix de -- pendant cette période. En général, les indicateurs techniques indiquent une tendance Sell à moyen terme.
Signaux haussiers/baissiers pour GNCAQ
Nous analysons les indicateurs clés comme les moyennes mobiles, le RSI, le MACD et le volume de transactions pour générer des signaux haussiers et baissiers pour GNCAQ, vous aidant à prendre des décisions d'investissement éclairées.
Questions complémentaires
Comment les indicateurs d'analyse technique s'appliquent-ils à GNCAQ ?
Quels sont les niveaux de retracement de Fibonacci pour GNCAQ ?
Quel est le RSI de Genocea Biosciences Inc ?
Quel est le prix de Genocea Biosciences Inc pour les 12 prochains mois ?